Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Addendum
Announcement
Announcements
Author’ response
Author’s reply
Authors' response
Authors#x2019; response
Book Received
Book Review
Book Reviews
Books Received
Centenary Review Article
Clinical Image
Clinical Images
Commentary
Communicable Diseases - Original Articles
Correspondence
Correspondence, Letter to Editor
Correspondences
Correspondences & Authors’ Responses
Corrigendum
Corrrespondence
Critique
Current Issue
Editorial
Editorial Podcast
Errata
Erratum
FORM IV
GUIDELINES
Health Technology Innovation
IAA CONSENSUS DOCUMENT
Innovations
Letter to Editor
Malnutrition & Other Health Issues - Original Articles
Media & News
Notice of Retraction
Obituary
Original Article
Original Articles
Panel of Reviewers (2006)
Panel of Reviewers (2007)
Panel of Reviewers (2009) Guidelines for Contributors
Perspective
Policy
Policy Document
Policy Guidelines
Policy, Review Article
Policy: Correspondence
Policy: Editorial
Policy: Mapping Review
Policy: Original Article
Policy: Perspective
Policy: Process Paper
Policy: Scoping Review
Policy: Special Report
Policy: Systematic Review
Policy: Viewpoint
Practice
Practice: Authors’ response
Practice: Book Review
Practice: Clinical Image
Practice: Commentary
Practice: Correspondence
Practice: Letter to Editor
Practice: Method
Practice: Obituary
Practice: Original Article
Practice: Pages From History of Medicine
Practice: Perspective
Practice: Review Article
Practice: Short Note
Practice: Short Paper
Practice: Special Report
Practice: Student IJMR
Practice: Systematic Review
Pratice, Original Article
Pratice, Review Article
Pratice, Short Paper
Programme
Programme, Correspondence, Letter to Editor
Programme: Authors’ response
Programme: Commentary
Programme: Correspondence
Programme: Editorial
Programme: Original Article
Programme: Originial Article
Programme: Perspective
Programme: Rapid Review
Programme: Review Article
Programme: Short Paper
Programme: Special Report
Programme: Status Paper
Programme: Systematic Review
Programme: Viewpoint
Protocol
Public Notice
Research Brief
Research Correspondence
Retraction
Review Article
Reviewers
Short Paper
Some Forthcoming Scientific Events
Special Article
Special Opinion Paper
Special Report
Special Section Nutrition & Food Security
Status Paper
Status Report
Strategy
Student IJMR
Systematic Article
Systematic Review
Systematic Review & Meta-Analysis
View Point
Viewpoint
White Paper
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Addendum
Announcement
Announcements
Author’ response
Author’s reply
Authors' response
Authors#x2019; response
Book Received
Book Review
Book Reviews
Books Received
Centenary Review Article
Clinical Image
Clinical Images
Commentary
Communicable Diseases - Original Articles
Correspondence
Correspondence, Letter to Editor
Correspondences
Correspondences & Authors’ Responses
Corrigendum
Corrrespondence
Critique
Current Issue
Editorial
Editorial Podcast
Errata
Erratum
FORM IV
GUIDELINES
Health Technology Innovation
IAA CONSENSUS DOCUMENT
Innovations
Letter to Editor
Malnutrition & Other Health Issues - Original Articles
Media & News
Notice of Retraction
Obituary
Original Article
Original Articles
Panel of Reviewers (2006)
Panel of Reviewers (2007)
Panel of Reviewers (2009) Guidelines for Contributors
Perspective
Policy
Policy Document
Policy Guidelines
Policy, Review Article
Policy: Correspondence
Policy: Editorial
Policy: Mapping Review
Policy: Original Article
Policy: Perspective
Policy: Process Paper
Policy: Scoping Review
Policy: Special Report
Policy: Systematic Review
Policy: Viewpoint
Practice
Practice: Authors’ response
Practice: Book Review
Practice: Clinical Image
Practice: Commentary
Practice: Correspondence
Practice: Letter to Editor
Practice: Method
Practice: Obituary
Practice: Original Article
Practice: Pages From History of Medicine
Practice: Perspective
Practice: Review Article
Practice: Short Note
Practice: Short Paper
Practice: Special Report
Practice: Student IJMR
Practice: Systematic Review
Pratice, Original Article
Pratice, Review Article
Pratice, Short Paper
Programme
Programme, Correspondence, Letter to Editor
Programme: Authors’ response
Programme: Commentary
Programme: Correspondence
Programme: Editorial
Programme: Original Article
Programme: Originial Article
Programme: Perspective
Programme: Rapid Review
Programme: Review Article
Programme: Short Paper
Programme: Special Report
Programme: Status Paper
Programme: Systematic Review
Programme: Viewpoint
Protocol
Public Notice
Research Brief
Research Correspondence
Retraction
Review Article
Reviewers
Short Paper
Some Forthcoming Scientific Events
Special Article
Special Opinion Paper
Special Report
Special Section Nutrition & Food Security
Status Paper
Status Report
Strategy
Student IJMR
Systematic Article
Systematic Review
Systematic Review & Meta-Analysis
View Point
Viewpoint
White Paper
View/Download PDF
Original Article
163 (
6
); 710-719
doi:
10.25259/IJMR_3386_2025

Translate:

Targeted metabolomic profiling of gastric cancer biopsies

Author affiliations
Department of Molecular Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
Department of Medical Gastroenterology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
Department of Oncopathology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
Article History
Corresponding author(s)

For correspondence: Dr Gopal Gopisetty, Department of Molecular Oncology, Cancer Institute (WIA), Chennai 600 036, Tamil Nadu, India e-mail: ggopisetty@gmail.com

Article tools · PDF & citations

Abstract

Background and objectives

Gastric cancer, the fifth most diagnosed malignancy worldwide and seventh in India, exhibits high metabolic activity and marked heterogeneity. In this study, we performed targeted metabolomic profiling of gastric cancer biopsies obtained through esophagogastroduodenoscopy in a South Indian cohort.

Methods

Targeted metabolite profiling was conducted using liquid chromatography–mass spectrometry (LC–MS) analysis. Pathway enrichment and biomarker evaluation were performed using MetaboAnalyst 6.0, incorporating univariate analysis and receiver operating characteristic (ROC) curve assessment.

Results

LC-MS based analysis of tumour (n=25), paired normal (n=25), and normal gastric mucosa (n=3) samples revealed distinct metabolic alterations associated with gastric cancer. The metabolic profiles of tumours and paired normal tissues were similar when compared with normal mucosa, suggesting a potential field effect in gastric carcinogenesis. A total of 58 metabolites were identified, of which 44.8% comprising peptides, amino acids, and their derivatives showed marked upregulation in tumours, indicating enhanced amino acid metabolism. Elevated uracil and uridine levels suggested altered pyrimidine metabolism, reflecting increased nucleotide turnover and supporting rapid DNA/RNA synthesis. Pathway analysis highlighted modulation of arginine biosynthesis, serine–one carbon metabolism, and nucleotide metabolism in gastric cancer tissues. ROC analysis identified ornithine and citrulline as potential discriminators in gastric cancer.

Interpretation and conclusions

Our findings reveal differentially altered metabolites in gastric cancer that are predominantly involved in arginine, serine one-carbon, and nucleotide metabolism. Ornithine and citrulline were identified as potential diagnostic biomarkers and therapeutic targets.

Keywords

  • Arginine biosynthesis
  • Field cancerisation
  • Gastric cancer
  • LC-MS analysis
  • Metabolomic profiling
  • Pyrimidine metabolism
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Rangarajan A, Natarajan T, Lakshminarayanan S, Sundersingh S, Subramani J, Gopisetty G. Targeted metabolomic profiling of gastric cancer biopsies. Indian J Med Res. 2026;163:710-9. doi: 10.25259/IJMR_3386_2025

Gastric cancer ranks fifth among the most frequently diagnosed cancers worldwide and seventh in India.1,2 The principal diagnostic approach for gastric carcinoma involves esophagogastroduodenoscopy, followed by biopsy and histopathological examination. Serum biomarkers- carcinoembryonic antigen and carbohydrate antigen 19-9 (CA 19-9) are mainly used for monitoring recurrence; however, none are specific for diagnosis of gastric cancer.3 Most patients present with advanced-stage disease, resulting in poor survival outcomes and highlighting the urgent need for sensitive biomarkers for early detection and prevention of this disease.4,5

Metabolic rewiring is a hallmark of cancer, allowing malignant cells to alter their metabolism to meet elevated energy and biosynthetic demands during tumorigenesis.6 One of the earliest and most extensively studied features of cancer metabolism is the Warburg effect, described by Otto Warburg, in which cancer cells preferentially convert glucose to lactate, even under aerobic conditions.7 Metabolite profiling has diagnostic and predictive potential, including a 17-metabolite panel that distinguishes papillary thyroid carcinoma and predicts non-small cell lung Cancer treatment response.8,9 In gastric cancer, elevated lactate levels correlate with aggressiveness, while reduced α-linolenic, linoleic and palmitic acid levels and stage-specific alterations in IDO1-mediated tryptophan metabolism suggest potential biomarker relevance.10,11 Profiling patients of gastric cancer with peritoneal metastasis identified a set of metabolites, such as triglycerides, dodecanal, tetradecanoic acid, and myristate, reported as independent risk factors for metastasis.12 Similarly, plasma-based targeted metabolomics has shown alterations in tryptophan and nitrogen metabolism, where histidine, tryptophan, and phenylacetylglutamine were suggested as potential discriminators.13 In parallel, tissue metabolomic profiling of gastric cancer reveals dysregulation of glycerophospholipid metabolism linked to disease progression.14 Previous tissue-based metabolomic studies, including DESI-MSI analysis of prostate cancer, have shown that alterations in small metabolites can contribute to discrimination between tumour and benign tissues.15 Broadly, metabolite profiles across plasma, serum, and tissue samples are explored for risk stratification and prognostic assessment. Clinically, blood-based metabolomics could guide minimally invasive monitoring and prognostic assessment, whereas tissue metabolites provide tumour-specific insights for diagnosis and therapeutic decision-making.16,17 Considering the heterogeneous nature of the disease and in line with these previous findings, we performed targeted metabolomic profiling of gastric cancer in a cohort of patients from South India and identified significantly altered metabolites that may act as potential diagnostic markers for gastric cancer.

Methods

This comparative observational study was undertaken by the department of Molecular Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India. Written informed consent was obtained from all participants, and ethical clearance was granted by the Institutional ethics committee.

Sample collection

A total of 53 treatment naive gastric tissue specimens were collected, including 25 tumour tissues, 25 matched paired normal tissues, and 3 apparent normal gastric tissues from non-diseased individuals. Samples were collected from patients undergoing esophagogastroduodenoscopy at the Cancer Institute (WIA), Chennai, either for the diagnosis of gastric cancer or during routine screening during the period from January 2021 to December 2023. Immediately after collection, tissues were snap-frozen and stored at -80°C until further processing. Tissue morphology was examined using haematoxylin and eosin (H&E) staining to confirm tumour cellularity in cancer tissues and verify the absence of malignancy in paired and apparent normal samples.

Metabolite extraction and LC-MS analysis for targeted metabolomics

Metabolite extractions were performed using the LC/MS/MS method package for primary metabolites, Version 3 (Shimadzu, Japan), following the manufacturer’s instructions. Equal amounts of tissues were used for extraction across all samples to minimise variability arising from sample input. 10 µmol/L L-methionine sulfone and 2-(N-morpholino) ethanesulfonic acid MES were added as internal standards to each sample prior to extraction and served as quality control markers to monitor extraction efficiency and analytical stability throughout the analytical run. Breifly, 10 mg of tissue was homogenised in 500 µL methanol containing internal standards using an ultrasonic bath for 10 min. After homogenisation, 250 µL ultrapure water was added, followed by the addition of 400 µL chloroform to 600 µL of the homogenate to facilitate phase separation. The mixture was centrifuged at 15,000 rpm for 15 min at 4 °C, and the aqueous supernatant was collected, dried, and reconstituted in 60 µL of LC–MS grade water.

For metabolite profiling, 5 µL of the extract was injected into an LCMS-8060 NX triple-quadrupole mass spectrometer (Shimadzu, Kyoto, Japan) equipped with a negative ion ESI source. A total of 143 metabolites were separated using a Shim-pack GIST PFPP column (3 µm, 2.1 × 150 mm; Shimadzu) with mobile phases A (0.1% formic acid in water) and B (0.1% formic acid in acetonitrile). A ten-step gradient (0–2 min, 100% A; 2–5 min, 75% A/25% B; 5–11 min, 65% A/35% B; 11–12.5 min, 50% A/50% B; 12.5–16 min, 50% A/50% B; 16.01–19 min, 5% A/95% B; 19.01–30 min, 100% A) was applied at a flow rate of 0.25 mL/min (0.5 mL/min from 17–19 min). An additional 114 metabolites were separated using a Mastro2 C18 ion-pair column (3 µm, 2.0 × 150 mm; Shimadzu GLC) with mobile phase A (15 mM acetic acid, 10 mM dipentylamine in water) and mobile phase B (methanol). A six-step gradient was run at 0.3 mL/min as follows: 0–0.5 min, 100% A; 0.5–8 min, 85% A/15% B; 8–12 min, 2% A/98% B; 12–15 min, 2% A/98% B; 15.1–20 min, 100% A. The instrument was operated with a nebulising gas flow rate of 3 L/min for the PFPP mode and 2 L/min for the ion-pair mode, drying and heating gas flow of 10 L/min, and interface, DL, and heat block temperatures of 270°C, 250°C, and 400°C, respectively. The data were acquired and processed using LabSolutions and Multi-Omics data analysis package (Shimadzu, Kyoto, Japan). Each sample was analysed in technical duplicates to ensure reproducibility and accuracy. All samples were processed and analysed in a single LC–MS analytical run.

Software

The metabolomic profiles of tumour and matched paired normal samples relative to apparent normal samples were determined using LabSolutions software and the Multi-Omics data analysis package (Shimadzu, Japan). Differential metabolites were identified based on log₂ fold change > 1.5 and P-values adjusted for multiple testing using the Benjamini–Hochberg false discovery rate (FDR) method. Pathway analysis was performed using MetaboAnalyst 6.0, employing the hypergeometric enrichment approach, with relative betweenness centrality as the topological parameter. For diagnostic marker evaluation, univariate analysis was conducted using the Biomarker Analysis module of MetaboAnalyst 6.0. Statistical significance between groups was determined using the built-in t-test in MetaboAnalyst, and metabolites with P<0.05 were considered significant.

Results

Clinical characteristics of the study group

The mean age of the study participants was 53.7 years, including 15 men and 10 women. Histopathological evaluation confirmed all tumour samples as adenocarcinoma, with 16 cases classified as Grade III and 6 as Grade II. According to Lauren classification, 16 cases were of the diffuse type and 9 were of the intestinal type. The majority of cases were non-cardia gastric cancers (Supplementary Figure A-C and Supplementary Table I).

Supplementary Figure

Supplementary Table I

Comparative metabolomic analysis reveals distinct metabolic alterations between apparent normal, paired normal, and tumour tissues

A total of 53 gastric tissue samples comprising tumour (TR, n=25), paired normal (PN, n=25), and apparent normal (AN, n=3) groups were subjected to targeted metabolomic profiling of 202 metabolites using an LCMS-8060 NX system (Shimadzu, Japan). The targeted metabolites were selected based on their biological relevance to gastric cancer metabolism, with coverage of key intermediates in central carbon, amino acid, nucleotide, and redox pathways, guided by prior gastric cancer metabolomics studies.18,19 The workflow for extraction and analysis is illustrated in a flowchart (Supplementary Figure D). Peak area data were processed and statistically evaluated using the LabSolutions and Multi-Omics data analysis package, with a cutoff value of log₂ fold change >1.5 and P<0.05, to identify differentially altered metabolites across the study groups. L-methionine sulfone was used as an internal control for normalisation. Initially, we compared the metabolite profiles of the apparent normal versus tumour and apparent normal versus paired normal groups.

Differentially altered metabolites across study groups

We identified 21 metabolites (12 nucleotide, nucleoside, and purine derivatives; 6 peptides, amino acids, and derivatives; 2 coenzymes; and 1 organic acid) that were significantly downregulated in tumour samples and 19 metabolites (10 nucleotide, nucleoside, and purine derivatives; 5 peptides, amino acids, and derivatives; 3 coenzymes; and 1 organic acid) in paired normal samples compared to the apparent normal samples. In contrast, 37 metabolites (26 amino acids, 5 organic and organophosphorus acids, 1 sugar, and 5 nucleoside and purine derivatives) in tumours and 38 metabolites (26 amino acids, 6 organic and organophosphorus acids, 1 sugar, and 5 nucleoside and purine derivatives) in paired normal tissues were significantly upregulated compared to apparent normal (AN) Gastric cancer tissues. Compared with AN tissues, tumour samples showed increased histidine levels accompanied by decreased histamine. This metabolic pattern prompted us to examine the expression status of histidine decarboxylase (HDC) using the GEPIA database, which revealed that HDC is downregulated in gastric cancer, indicating diminished histidine-to-histamine conversion. Together, tumour tissues also exhibited elevated levels of fructose 1,6-bisphosphate, lactic acid, and phosphoenolpyruvic acid, key intermediates of the glycolytic pathway ( Figs. 1A-D, 2A-C and Supplementary Table II-IV).

Supplementary Table II

Supplementary Table III

Supplementary Table IV
Targeted metabolomic profiling of gastric cancer identifies significantly altered metabolites (log₂ fold change >1.5, P<0.05). Volcano plots of differentially expressed metabolites in apparent normal (AN) versus tumour (TR) tissues using Ion pairing (A) and PFPP (B) columns. Volcano plots of differentially expressed metabolites in AN versus paired normal (PN) tissues using Ion pairing (C) and PFPP (D) columns.
Fig. 1. Targeted metabolomic profiling of gastric cancer identifies significantly altered metabolites (log₂ fold change >1.5, P<0.05). Volcano plots of differentially expressed metabolites in apparent normal (AN) versus tumour (TR) tissues using Ion pairing (A) and PFPP (B) columns. Volcano plots of differentially expressed metabolites in AN versus paired normal (PN) tissues using Ion pairing (C) and PFPP (D) columns.

A comparison of tumour and paired normal profiles revealed that 18 metabolites were significantly downregulated and 36 were significantly upregulated in both groups relative to apparent normal tissues, suggesting that the metabolic profile of adjacent matched tissues changes during cancer progression ( Fig. 2D). For tumour-specific changes, we compared tumour and paired normal samples and identified seven metabolites (thymine, 4-hydroxyproline, 5-glutamyl cysteine, citrulline, methionine sulfoxide, ornithine, and S-adenosylmethionine) that were significantly upregulated and 13 metabolites (FAD, uridine, inosine, guanosine, cytidine, cytidine 3’-5’ cyclic monophosphate, cytidine monophosphate, cytosine, ophthalmic acid, creatine, arginine, histamine, and pantothenic acid) that were downregulated ( Figs. 2E, F and Supplementary Table V).

Supplementary Table V
Differentially altered metabolites in gastric cancer (log₂ fold change >1.5, P < 0.05). (A-B) Expression levels of histamine and histidine in apparent normal (AN, n=3), tumour (TR, n=25), and paired normal (PN, n=25) tissues. Each dot represents an individual sample; samples were run in duplicates. (C) Gene expression profile of Histidine Decarboxylase (HDC) in gastric cancer obtained from the GEPIA database. Each dot represents the expression level of an individual sample. Here, T is tumour and N is normal. (D) Venn diagram showing the overlap of differentially expressed metabolites in gastric cancer. Volcano plots of differentially expressed metabolites in PN versus TR tissues using (E) Ion pairing and (F) PFPP columns.
Fig. 2. Differentially altered metabolites in gastric cancer (log₂ fold change >1.5, P < 0.05). (A-B) Expression levels of histamine and histidine in apparent normal (AN, n=3), tumour (TR, n=25), and paired normal (PN, n=25) tissues. Each dot represents an individual sample; samples were run in duplicates. (C) Gene expression profile of Histidine Decarboxylase (HDC) in gastric cancer obtained from the GEPIA database. Each dot represents the expression level of an individual sample. Here, T is tumour and N is normal. (D) Venn diagram showing the overlap of differentially expressed metabolites in gastric cancer. Volcano plots of differentially expressed metabolites in PN versus TR tissues using (E) Ion pairing and (F) PFPP columns.

Upregulated metabolites were primarily involved in amino acid metabolism, methylation, and redox regulation, whereas downregulated metabolites were enriched in nucleotide metabolism and energy-related pathways. The substantial overlap in differential metabolites between PN and TR tissues compared to AN prompted subsequent analysis to focus on AN versus TR, emphasising tumour-specific metabolic alterations.

Altered metabolic pathways in gastric cancer: arginine biosynthesis, one-carbon metabolism, and pyrimidine metabolism

We further investigated the biological functions of the altered metabolites in tumours. Pathway analyses revealed that three major pathways were found to be dysregulated in gastric cancer: arginine biosynthesis, pyrimidine metabolism, and the serine-one-carbon metabolism pathway. In the arginine biosynthesis pathway, metabolites such as citrulline, ornithine, arginine, and L-argininosuccinic acid were significantly upregulated in tumour tissues, suggesting enhanced polyamine synthesis and increased urea cycle activity that may facilitate tumour growth and proliferation. To further validate these metabolomic findings, we retrieved the gene expression profiles of key enzymes involved in arginine synthesis, including ornithine transcarbamylase (OTC), ornithine decarboxylase (ODC1), argininosuccinate synthase 1 (ASS1), and argininosuccinate lyase (ASL) from the GEPIA database. Consistent with the observed metabolite trends, the expression of OTC, ASS1, ASL and ODC1 was upregulated in gastric cancer, indicating an overall activation of the arginine biosynthetic pathway ( Figs. 3A-D).

Pathway analysis using MetaboAnalyst 6.0 reveals modulation of arginine biosynthesis in gastric cancer. (A) Upregulation of arginine biosynthesis in gastric cancer. (B-C) Expression levels of citrulline and ornithine in apparent normal (AN, n = 3), tumour (TR, n=25), and paired normal (PN, n = 25) tissues. Each dot represents an individual sample; duplicates were run. (D) Gene expression profile of ornithine transcarbamylase (OTC), argininosuccinate synthase 1 (ASS1), argininosuccinate lyase (ASL) and ornithine decarboxylase (ODC1) in gastric cancer obtained from the GEPIA database. Each dot represents the expression level of an individual sample [Tumour (T) and Normal(N)].
Fig. 3. Pathway analysis using MetaboAnalyst 6.0 reveals modulation of arginine biosynthesis in gastric cancer. (A) Upregulation of arginine biosynthesis in gastric cancer. (B-C) Expression levels of citrulline and ornithine in apparent normal (AN, n = 3), tumour (TR, n=25), and paired normal (PN, n = 25) tissues. Each dot represents an individual sample; duplicates were run. (D) Gene expression profile of ornithine transcarbamylase (OTC), argininosuccinate synthase 1 (ASS1), argininosuccinate lyase (ASL) and ornithine decarboxylase (ODC1) in gastric cancer obtained from the GEPIA database. Each dot represents the expression level of an individual sample [Tumour (T) and Normal(N)].

Alterations in pyrimidine metabolism were observed as decreased levels of CMP and cytidine, accompanied by increased uridine and uracil levels, indicating increased nucleotide turnover and potential support for rapid DNA/RNA synthesis in cancer cells ( Fig. 4A). We observed increased levels of serine, glycine, and methionine, which are key intermediates of one-carbon metabolism, accompanied by decreased ATP, S-adenosyl-L-methionine (SAM), S-adenosyl-L-homocysteine (SAH), and homocysteine levels, with a concurrent increase in adenosine levels. These coordinated changes suggest alterations in one-carbon metabolism and methionine cycle activity in tumour tissues ( Fig. 4B).

Pathway and biomarker analysis reveal key metabolic alterations in gastric cancer. (A–B) Alterations in pyrimidine metabolism and serine–one-carbon metabolism pathways, with key metabolites showing differential abundance in gastric cancer tissues (e.g., uridine, serine). (C-D) Area under the curve (AUC) values with 95% confidence intervals were calculated using univariate analysis, and statistical significance was evaluated using Student’s t-test (P<0.05). ROC curves comparing paired normal (PN) versus tumour (TR) tissues.
Fig. 4. Pathway and biomarker analysis reveal key metabolic alterations in gastric cancer. (A–B) Alterations in pyrimidine metabolism and serine–one-carbon metabolism pathways, with key metabolites showing differential abundance in gastric cancer tissues (e.g., uridine, serine). (C-D) Area under the curve (AUC) values with 95% confidence intervals were calculated using univariate analysis, and statistical significance was evaluated using Student’s t-test (P<0.05). ROC curves comparing paired normal (PN) versus tumour (TR) tissues.

Evaluation of diagnostic potential of differential metabolites between tumour and apparent normal tissues

To evaluate the diagnostic potential of the differentially expressed metabolites, a receiver operator characteristic (ROC) curve analysis was performed using the classical univariate ROC module in MetaboAnalyst 6.0. Univariate analysis using Student’s t-test was used to assess the statistical significance between the groups. Metabolites demonstrating good discriminatory performance between tumour (TR) and apparent normal (AN) tissues, defined by an area under the curve (AUC) > 0.8 with corresponding 95% confidence intervals (95% CI) are listed in Supplementary Table VI. AUC values ranged from 0.5 (no discrimination) to 1.0 (perfect discrimination), with higher values indicating stronger diagnostic potential. Adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), guanosine triphosphate (GTP), uridine monophosphate (UMP), uridine diphosphate (UDP), uracil, and cytidine cyclic monophosphate (cCMP) exhibited significantly good area under the curve (AUC) values. These metabolites, representing nucleotides and their derivatives, may serve as a potential discriminative panel distinguishing tumour from control gastric tissues. Ornithine (AUC=0.96) and citrulline (AUC=0.97), both belonging to the arginine biosynthesis pathway, exhibited strong discriminative ability between tumour (TR) and apparent normal (AN) tissues. Similarly, ROC analysis comparing paired normal (PN) and tumour (TR) samples also identified ornithine and citrulline as good discriminators in gastric cancer ( Figs. 4C-D and Supplementary Table VI). These results highlight the diagnostic and metabolic importance of arginine synthesis and nucleotide metabolism in gastric cancer biomarker profiling.

Supplementary Table VI

Discussion

Gastric cancer is a highly metabolic and heterogeneous disease with significant intratumor and intertumour variability.20,21 In this study we performed metabolomic profiling of gastric cancer tissues from a South Indian cohort to characterise metabolic alterations and to identify potential diagnostic biomarkers. Analysis revealed distinct alterations in the metabolomic profiles of tumours compared to apparent normal tissues with a pronounced increase in amino acid metabolism in gastric cancer. Several metabolites were similarly altered in both tumour and paired normal relative to apparent normal gastric tissues obtained from unaffected stomach. Metabolites such as ornithine, citrulline, histidine, and histamine demonstrated a gradual trend of either increasing or decreasing abundance from apparent normal to paired normal to tumour tissues. Pathway analysis of altered metabolites revealed that arginine biosynthesis, serine-one carbon metabolism, and pyrimidine synthesis were modulated in gastric cancer. The diagnostic potential of altered metabolites was evaluated using ROC analysis, which showed that a panel of metabolites involved in arginine biosynthesis and nucleotide metabolism has good discriminatory power between tumour and normal tissues.

The results were found to be in line with previous studies, where metabolomic analysis of 80 gastric cancer tissues and their matched normal counterparts using LC–MS reported elevated levels of amino acids known to promote tumour cell proliferation and biomass synthesis.22 Previous gastric cancer tissue metabolomic studies have primarily reported dysregulation of amino acid metabolism involving valine, isoleucine, serine, with β-alanine identified as an independent predictor of peritoneal recurrence.23,24 Although a recent study reported increased citrulline in gastric cancer, they have largely focused on phosphatidylcholines, fatty acids, and acylcarnitines as diagnostic and TNM-associated markers.22 In the context of existing gastric cancer metabolomics literature, our findings demonstrate elevated levels of both citrulline and ornithine in tumour tissues. Together with the reported upregulation of OTC, ASS1, and ODC1 in gastric cancer (GEPIA), these alterations may contribute to diagnostic potential and reflect dysregulation of the urea cycle.25 Ornithine plays an additional role in polyamine synthesis, and polyamines are known to promote tumour proliferation and maintain genomic stability in gastric cancer.26 Metabolomic profiling of plasma samples from gastric cancer patients has shown decreased ornithine levels, suggesting that ornithine may be extensively utilised by tumour tissues for bioenergy production and biosynthetic processes.27 Elevated levels of lactate and phosphoenolpyruvate demonstrate the classical Warburg effect.28 Although the paired normal tissues appeared histologically normal, they exhibited distinct metabolic alterations, suggesting a possible field effect that describes the phenomenon in which prolonged exposure to carcinogenic agents induces molecular and cellular alterations across an epithelial region, predisposing cells toward malignant transformation through progressive precancerous changes in the gastric mucosa.29 Our observations are consistent with the findings in oesophageal adenocarcinoma, where metabolomic profiling using 1H magic angle spinning–NMR spectroscopy has revealed a metabolic field effect in histologically normal mucosa adjacent to tumours, reinforcing the concept of stepwise metabolic transformation in cancer development.30 Pathway analysis results align with previous studies implicating the role of arginine in tumorigenesis. For instance, in breast cancer, arginine promotes tumour growth through immune evasion, either by suppressing the cytotoxic activity of CD8⁺ T cells or by inducing pro-tumour polarisation of tumour-associated macrophages (TAMs).31 Arginine also serves as a key precursor for nitric oxide (NO) synthesis, a signalling molecule known to promote angiogenesis and cancer cell proliferation, thereby supporting the role of enhanced arginine metabolism in tumour progression.32 Together, uridine can serve as an alternative energy source under glucose-limited conditions and may contribute to tumorigenesis by supporting nucleotide synthesis and energy production.33,34 Similarly, in gingivo-buccal oral squamous cell carcinoma (GB-OSCC), uracil was found to be upregulated in 83.1% of tumour tissues, indicating active pyrimidine metabolism and suggesting its potential as a prognostic or predictive biomarker for monitoring recurrence.35

Metabolomic studies in gastric cancer tissue, particularly in Indian populations, are limited, and given the heterogeneity of gastric cancer, the current work contributes to the understanding of metabolic alterations in this population. A limitation of this study is the small number of apparent normal gastric tissues, which restricted the statistical power of AN-related comparisons. This limitation arises from practical constraints in obtaining gastric biopsies from non-diseased individuals. Accordingly, comparisons involving the AN group were interpreted cautiously and should be considered exploratory. Chronic gastritis and Helicobacter pylori infection are highly prevalent in the gastric mucosa of patients with gastric cancer and are known to induce metabolic changes that may resemble early neoplastic alterations. Since our study did not systematically assess gastritis grade or H. pylori status, these factors could act as confounders and may contribute to the observed similarity between tumor and paired samples. The apparently normal sample size (n=3) may inflate ROC AUC estimates, but ornithine and citrulline also showed discrimination in paired normal–tumour comparisons.

Overall, the identified metabolic alterations highlight key biochemical pathways that may contribute to early diagnosis and could serve as potential therapeutic targets in gastric cancer. Ornithine and citrulline were identified as potential diagnostic biomarkers and therapeutic targets.

Acknowledgment

Author acknowledge SPINCO Technologies and Shimadzu for providing the mass spectrometry equipment and software used in this study.

Author contributions

AR: Acquisition of data, analysis and interpretation of data, manuscript writing; JS: Acquisition of LC-MS data; TN, SL: Sample resource; SSS: Analysis and interpretation of histology data; GG: Conception and design, analysis and interpretation of data, manuscript writing. All authors have read and approve the final printed version of the manuscript.

Financial support and sponsorship

The study received funding support from DST-SERB (CRG/2020/000877) and DST-WISE-KIRAN (DST/WISE-PhD/LS/2024/280).

Conflicts of Interest

None.

Use of Artificial Intelligence (AI)-Assisted Technology for manuscript preparation

The authors confirm that there was no use of AI-assisted technology for assisting in the writing of the manuscript and no images were manipulated using AI.

References

  1. , . Epidemiology of gastric cancer: Global trends, risk factors and prevention. Prz Gastroenterol.. 2019;14:26-38.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  2. , , , , , . Epidemiological trends and patterns of gastric cancer in the Kashmir Valley, India. Clin Epidemiol Glob Health.. 2025;34:102057.
    [CrossRef] [Google Scholar]
  3. , , , , , , et al. Landscape of Innovative methods for early diagnosis of gastric cancer: A systematic review. Diagnostics (Basel).. 2023;13:3608.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  4. , , , . Changing trends in stomach cancer throughout the World. Curr Gastroenterol Rep.. 2017;19:36.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  5. , , , . Surgical and survival outcomes of operable gastric cancer: Experience from a tertiary care center in South India. Indian J Surg Oncol.. 2023;14:48-52.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  6. , . Metabolites and the tumour microenvironment: From cellular mechanisms to systemic metabolism. Nat Metab.. 2021;3:21-32.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  7. , , , , . Exploring the role of metabolites in cancer and the associated nerve crosstalk. Nutrients.. 2022;14:1722.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  8. , , , , , , et al. Combined metabolomics with transcriptomics reveals potential plasma biomarkers correlated with non-small-cell lung cancer proliferation through the Akt pathway. Clin Chim Acta.. 2022;530:66-73.
    [CrossRef] [PubMed] [Google Scholar]
  9. , , , , , , et al. Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer. Oncogene.. 2022;41:2422-30.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  10. , , , , , , et al. Identification and validation of plasma metabolomic signatures in precancerous gastric lesions that progress to cancer. JAMA Netw Open.. 2021;4:e2114186.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  11. , , , , , , et al. IDO1-mediated catabolism of tryptophan in gastric tumors: Its potential role in the axis of histopathology, differentiation and metastasis. Pathol Res Pract.. 2024;263:155655.
    [CrossRef] [PubMed] [Google Scholar]
  12. , , , , , , et al. Discovering biomarkers in peritoneal metastasis of gastric cancer by metabolomics. Onco Targets Ther.. 2020;13:7199-211.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  13. , , , , , , et al. Plasma sample based analysis of gastric cancer progression using targeted metabolomics. Sci Rep.. 2017;7:17774.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  14. , , , , , , et al. 1H NMR metabolic profiling of gastric cancer patients with lymph node metastasis. Metabolomics.. 2018;14:47.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  15. , , , , , , et al. Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids. Proc Natl Acad Sci USA.. 2017;114:3334-9.
    [CrossRef] [Google Scholar]
  16. , , , , , , et al. Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: A large-scale, multicentre study. Gut.. 2023;72:2051-67.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  17. , , , , , , et al. Tissue-based metabolomics reveals metabolic signatures and major metabolic pathways of gastric cancer with help of transcriptomic data from TCGA. Biosci Rep.. 2021;41:BSR20211476.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  18. , , , , , , et al. A systematic review of metabolomic profiling of gastric cancer and esophageal cancer. Cancer Biol Med.. 2020;17:181-98.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  19. , . Metabolomic studies of human gastric cancer: Review. World J Gastroenterol.. 2014;20:8092-101.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  20. , , , , . Unraveling metabolic characteristics and clinical implications in gastric cancer through single-cell resolution analysis. Front Mol Biosci.. 2024;11:1399679.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  21. , , , , . Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell. World J Gastroenterol.. 2018;24:2567-81.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  22. , , , , , , et al. Metabolic Reprogramming of gastric cancer revealed by a liquid chromatography–mass spectrometry-based metabolomics study. Metabolites.. 2025;15:222.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  23. , , , , , , et al. Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry. Anal Bioanal Chem.. 2010;396:1385-95.
    [CrossRef] [PubMed] [Google Scholar]
  24. , , , , , , et al. Metabolomic profiling of gastric cancer tissues identified potential biomarkers for predicting peritoneal recurrence. Gastric Cancer.. 2020;23:874-83.
    [CrossRef] [PubMed] [Google Scholar]
  25. , , . Physiology, Urea cycle. In: StatPearls. . Treasure Island (FL): StatPearls Publishing; .
    [Google Scholar]
  26. , , . The role of polyamines in gastric cancer. Oncogene.. 2021;40:4399-412.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  27. , , , , , , et al. Prognostic implication of plasma metabolites in gastric cancer. Int J Mol Sci.. 2023;24:12774.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  28. , , , , , , et al. Clinical impact of the Warburg effect in gastrointestinal cancer. Int J Oncol.. 2014;45:1345-54.
    [CrossRef] [PubMed] [Google Scholar]
  29. , , . A computational model for the cancer field effect. Front Artif Intell.. 2023;6:1060879.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  30. , , , , , , et al. Metabolomic evidence for a field effect in histologically normal and metaplastic tissues in patients with esophageal adenocarcinoma. Neoplasia.. 2017;19:165-74.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  31. , , , , , , et al. Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion. Cancer Cell.. 2025;43:1045-60.
    [CrossRef] [PubMed] [Google Scholar]
  32. , . Arginine and the metabolic regulation of nitric oxide synthesis in cancer. Dis Model Mech.. 2018;11:dmm033332.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  33. , , , , , , et al. Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Nature.. 2023;618:151-8.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  34. , , , . Uridine as a hub in cancer metabolism and RNA biology. Exp Mol Med.. 2025;57:1651-62.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  35. , , , , , , et al. Uracil as a biomarker for spatial pyrimidine metabolism in the development of gingivobuccal oral squamous cell carcinoma. Sci Rep.. 2024;14:11609.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
Show Sections
Scroll to Top